tiprankstipranks

Reata downgraded to Market Perform from Outperform at SVB Securities

SVB Securities downgraded Reata Pharmaceuticals (RETA) to Market Perform from Outperform with a price target of $172.50, up from $115, after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on RETA:

Disclaimer & DisclosureReport an Issue